Streetbeat News

Earnings

CRI

Carter's, Inc. (CRI) forecasts low single-digit growth in net sales reaching around $3B for FY24, slightly above the $2.98B estimate. The company also anticipates mid-single-digit growth in adjusted diluted EPS.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:17 am

CRI

Carter's Q4 adjusted EPS of $2.76 exceeded the $2.63 estimate, a 20.52% increase YOY. However, sales of $857.86M fell short of the $869.05M estimate, marking a 5.95% decrease YOY.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:14 am

LDI

LoanDepot anticipates incurring expenses between $12M-$17M in Q1 2024 due to a previously announced cybersecurity incident. However, the company does not expect this to have a material impact on its full-year results.

Portfolio Pulse from Charles Gross

February 27, 2024 | 11:12 am

TIGO

Millicom has announced its confidence in achieving its target equity free cash flow of approximately $550 million by 2024. This statement underscores the company's strong financial position and its strategic plans aimed at realizing this goal.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:11 am

ESPR

Esperion Therapeutics forecasts its FY24 operating expenses to be between $225M-$245M, which includes $20M in non-cash expenses due to stock compensation.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:10 am

TIGO

Millicom Intl Cellular (NASDAQ:TIGO) reported a significant decrease in its quarterly earnings, posting a loss of $(0.37) per share compared to a gain of $0.33 per share in the same period last year, marking a 212.12% decrease.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:09 am

HSIC

Henry Schein anticipates its sales growth for the fiscal year 2024 to range between 8% to 12% over the figures reported in 2023, indicating a positive outlook for the company's financial performance in the upcoming year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:06 am

LOW

Lowe's Companies (NYSE:LOW) reported Q4 earnings of $1.77 per share, surpassing the $1.68 estimate, marking a 5.36% beat and a 12.03% increase from last year. Q4 sales reached $18.60 billion, exceeding the $18.45 billion estimate by 0.82%, despite a 17.12% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:06 am

ESPR

Esperion Therapeutics reported a 44% year-over-year growth in Q4 retail prescription equivalents and projects continued momentum in this segment into the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:06 am

TIGO

Millicom Intl Cellular (NASDAQ:TIGO) reported Q4 sales of $1.48 billion, surpassing the analyst consensus estimate of $1.45 billion by 1.72% and marking a 6.81% increase from $1.38 billion in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 11:05 am